idarubicin has been researched along with vorinostat in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bueso-Ramos, C; Garcia-Manero, G; Hoshino, K; Quintas-Cardama, A; Richon, VM; Sanchez-Gonzalez, B; Yang, H | 1 |
| Egorin, MJ; Espinoza-Delgado, I; Ferrajoli, A; Garcia-Manero, G; Holleran, JL; Kadia, TM; Kantarjian, HM; Madden, TL; Maddipotti, S; Newsome, W; Ravandi, F; Sanchez-Gonzalez, B; Schroeder, C; Thomas, DA; Yang, H; Zwiebel, JA | 1 |
| Bekele, NB; Borthakur, G; Brandt, M; Cortes, JE; de Lima, M; Faderl, S; Garcia-Manero, G; Hu, Y; Jabbour, E; Kadia, TM; Kantarjian, HM; Konopleva, MY; McCue, D; Newsome, WM; Pierce, SR; Ravandi, F; Tambaro, FP; Yang, H | 1 |
| Garcia-Manero, G | 1 |
| Aldayel, AS; Konoplev, S; Medeiros, LJ; Rich, A; Sun, J; Yin, CC | 1 |
| Amer, MM; Do, T; Galon, EM; Ji, S; Li, H; Liu, M; Ma, Y; Ma, Z; Xuan, X; Zafar, I | 1 |
3 review(s) available for idarubicin and vorinostat
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Clinical Trials, Phase I as Topic; Cytarabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Idarubicin; Leukemia, Myeloid, Acute; Vorinostat | 2012 |
Myelomastocytic leukemia with aberrant CD25 expression: case report and review of the literature.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; Brain; Cerebral Hemorrhage; Cytarabine; Fatal Outcome; Humans; Hydroxamic Acids; Idarubicin; Interleukin-2 Receptor alpha Subunit; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mast Cells; Middle Aged; Neoplasms, Second Primary; Neoplastic Stem Cells; Opportunistic Infections; Prostatectomy; Prostatic Neoplasms; Vorinostat | 2014 |
2 trial(s) available for idarubicin and vorinostat
| Article | Year |
|---|---|
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia.
Topics: Acetylation; Acute Disease; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinase Inhibitor p21; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Female; Histones; Humans; Hydroxamic Acids; Idarubicin; Leukemia; Leukemia, Myeloid, Acute; Male; Middle Aged; Poly-ADP-Ribose Binding Proteins; Recurrence; RNA, Messenger; Vorinostat; Young Adult | 2010 |
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Hydroxamic Acids; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Vorinostat | 2012 |
3 other study(ies) available for idarubicin and vorinostat
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor.
Topics: Acetylation; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Gene Expression Regulation, Leukemic; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; HL-60 Cells; Humans; Hydroxamic Acids; Idarubicin; Leukemia; Protein Processing, Post-Translational; RNA, Messenger; Valproic Acid; Vorinostat | 2006 |
In vitro screening of compounds from the Food and Drug Administration-approved library identifies anti-Babesia gibsoni activity of idarubicin hydrochloride and vorinostat.
Topics: Animals; Babesia; Babesiosis; Dog Diseases; Dogs; Idarubicin; Ixodidae; United States; United States Food and Drug Administration; Vorinostat | 2023 |